Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487078 | 0.79 | XDH (0.55) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL1014920 | 0.79 | XDH (0.55) | ADORA2AADORA1CDK2XDHRET | |
| Oxypurinol SCHEMBL8905886 | 0.78 | SMN1; SMN2 (0.37) | ADORA2AADORA1CDK2XDHRET | |
| Oxypurinol SCHEMBL8905476 | 0.78 | SMN1; SMN2 (0.37) | ADORA2AADORA1CDK2XDHRET | |
| Oxypurinol SCHEMBL5799552 | 0.78 | SMN1; SMN2 (0.37) | ADORA2AADORA1CDK2XDHRET | |
| Oxypurinol SCHEMBL8905835 | 0.78 | SMN1; SMN2 (0.37) | ADORA2AADORA1CDK2XDHRET | |
| Benzene SCHEMBL25427466 | 0.76 | RET (0.52) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL19891462 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL2629520 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL341706 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| EP-1232157-B1 | NON-AGGREGATING, NON-QUENCHING OLIGOMERS COMPRISING NUCLEOTIDE ANALOGUES; METHODS OF SYNTHESIS AND USE THEREOF | EPOCH BIOSCIENCES INC (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-6426408-B1 | PLURALITY OF NUCLEOTIDE UNITS WITH LINKING GROUP | EPOCH BIOSCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | MICROPROBE | 2002-05-02 | — | — | US | disclosed |
| US-6312894-B1 | HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6312925-B1 | EFFICIENT TARGETING AND MODIFICATION OF SEQUENCES IN DUPLEX DNA BY USING OLIGONUCLEOTIDE HAVING FIRST DOMAIN WHICH LOCALIZES TO VICINITY OF TARGET AND SECOND DOMAIN HAVING ATTACHED AGENT CAPABLE OF MODIFYING THE TARGET | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001038584-A2 | NON-AGGREGATING, NON-QUENCHING OLIGOMERS COMPRISING NUCLEOTIDE ANALOGUES; METHODS OF SYNTHESIS AND USE THEREOF | EPOCH BIOSCIENCES, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6084102-A | THE OLIGONUCLEOTIDE IS COMPLEMENTARY TO A TARGET SEQUENCE OF SINGLE STRANDED OR DOUBLE STRANDED DNA, RNA OR HYBRIDS AND, WHEN USED AS A PROBE, BINDS MORE STRONGLY BECAUSE OF THE BOUND MINOR GROVE BINDER; MEDICAL DIAGNOSIS; ANTISENSE THERAPY | EPOCH PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1998050541-A1 | METHODS AND COMPOSITIONS TO FACILITATE D-LOOP FORMATION BY OLIGONUCLEOTIDES | EPOCH PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0819133-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | EPOCH PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5659022-A | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids | EPOCH PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996032496-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | MICROPROBE CORPORATION (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | CD2BP2, MICA, SELPLG | ADORA2A 2876/4885ADORA1 3810/4885CDK2 2643/4885 |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | ADORA2A 353/4885ADORA1 831/4885CDK2 2701/4885 |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | ADORA2A 353/4885ADORA1 831/4885CDK2 2701/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | ADORA2A 353/4885ADORA1 831/4885CDK2 2701/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | ADORA2A 3772/4885ADORA1 4076/4885CDK2 3602/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | ADORA2A 353/4885ADORA1 831/4885CDK2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.